MET and familial pancreatic carcinoma: There are also some studies showed that elevated MET expression is a strong and independent risk factors of poor patient survival compared to RON, and the MET and RON co-expression does not appear to reflect a synergistic mechanism of reducing pancreatic cancer patient survival times (19).